2m 2m 2m 2m 2m 2m 2m
Fate Therapeutic (FATE)
NASDAQ
$2.40+$0.07 (+3.00%)
Price as of Aug 21, 2026 7:59 PM EDT- $279.2MMarket Cap
- 102.61%1-Year Change
- BiotechnologyIndustry
Fate Therapeutic (FATE)
$2.40+$0.07 (+3.00%)
FATE | vs History | vs S&P 500 | |
|---|---|---|---|
General Statistics | |||
Latest Close | $2.33 | ||
Change | -$0.12 (-4.90%) | ||
Open | $2.46 | ||
High | $2.51 | ||
Low | $2.32 | ||
Previous Close | $2.45 | ||
Volume | 1,697,067 | ||
30-Day Average Volume | 1,981,971 | ||
1-Week Change | -9.34% | ||
1-Month Change | -17.67% | ||
1-Year Change | 102.61% | ||
3-Year Change | -14.65% | ||
5-Year Change | -96.52% | ||
Fundamentals | |||
Shares Outstanding | 119.8M | ||
Total Assets | $260.1M | ||
Market Cap | $279.2M | ||
Enterprise Value | $246.8M | ||
Period: QTR TTM FY | |||
Revenue | $2.1M | ||
Net Income | -$30.2M | ||
Free Cash Flow | -$23.5M | ||
EBIT | -$30.2M | ||
EBITDA | -$27.4M | ||
Net Working Capital | $125.4M | ||
EPS | -$0.25 | ||
Enterprise Value/EBITDA | -9 | ||
Enterprise Value/Revenue | 119 | ||
P/B | 2 | ||
P/E | -9 | ||
PEG | -2 | ||
Price/Free Cash Flow | -12 | ||
Price/Operating Cash Flow | -12 | ||
Dividends & Splits | |||
Forward Annual Dividend Yield | N/A | ||
Trailing Annual Dividend Yield | N/A | ||
Ex-Dividend Date | N/A | ||
Last Split Factor | N/A | ||
Last Split Date | N/A | ||
Earnings & Revenue